Of note, patients with concurrent JAK2 and IDH1/2 mutations have shorter leukemia-free survival (11), suggesting that comutations in JAK2 and in IDH1/2 can promote MPN progression and transformation. Here, IDH1 is linked to myeloproliferative disorder.